Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT05522868 Recruiting - Solid Tumor Clinical Trials

SB17170 Phase 1 Clinical Trial in Solid Tumors

Start date: October 17, 2022
Phase: Phase 1
Study type: Interventional

Phase 1 Open-label, multicenter, dose escalation, dose expansion study

NCT ID: NCT05522491 Not yet recruiting - Solid Tumor Clinical Trials

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, single-center,exploratory clinical study.

NCT ID: NCT05512780 Not yet recruiting - Solid Tumor Clinical Trials

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

Start date: September 10, 2022
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label, exploratory clinical study

NCT ID: NCT05512208 Recruiting - Cervical Cancer Clinical Trials

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

DURAFAK
Start date: February 6, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or cervical cancer.

NCT ID: NCT05507736 Recruiting - Solid Tumor Clinical Trials

Feasibility and Safety of Acupuncture in the Prevention of Late Irinotecan-related Diarrhea in Pediatric Patients

AIP2021
Start date: January 15, 2022
Phase: N/A
Study type: Interventional

To evaluate the feasibility of an acupuncture protocol in the prevention of late diarrhea due to irinotecan in pediatric patients with solid tumors, a pre-post pilot study will be conducted. Pre-post pilot study non-randomized, open label, single arm study. There will be a single study group that will be used at the same time as your own control. The intervention will take place for approximately one year.

NCT ID: NCT05500508 Recruiting - Breast Cancer Clinical Trials

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Start date: November 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.

NCT ID: NCT05497453 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene

MYCHELANGELO I
Start date: August 19, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma (HCC) and other solid tumor types known for association with the MYC oncogene. The study consists of Part 1 (OTX-2002 monotherapy) and Part 2 (OTX-2002 combined with standard of care in hepatocellular carcinoma). Part 1 consists of escalation and expansion, and Part 2 consists of safety run-in and expansion. The objective of Part 1 escalation and Part 2 safety run-in will be safety and tolerability, while anti-tumor activity will be evaluated as the primary endpoint in Part 1 and Part 2 expansion.

NCT ID: NCT05494762 Active, not recruiting - Solid Tumor Clinical Trials

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

Start date: August 25, 2022
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid tumors.

NCT ID: NCT05490264 Recruiting - Solid Tumor Clinical Trials

[68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors

Start date: October 18, 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of [68Ga]Ga-NOTA-SNA002 and investigate the uptake of [68Ga]Ga-NOTA-SNA002 in patients with solid tumors.

NCT ID: NCT05485974 Recruiting - Cancer Clinical Trials

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Start date: August 1, 2022
Phase: Phase 1
Study type: Interventional

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.